Sensei Biotherapeutics

Sensei Biotherapeutics acquired Faeth Therapeutics and completed a $200 million private placement, refocusing its lead program on PIKTOR, an all-oral therapy targeting the PI3K/AKT/mTOR pathway. The new capital plus existing cash is expected to fund clinical operations through key 2026 milestones, including Phase 2 data in endometrial cancer and a Phase 1b trial in breast cancer. For 2025 the company reduced R&D and G&A spending, narrowing its net loss to $21.1 million, and while cash and marketable securities fell to $21.2 million at year-end, the subsequent financing substantially strengthens the balance sheet. » Plus sur finance.yahoo.com

Sensei’s stock surged about 200% after the announcement of the Faeth Therapeutics acquisition and a private placement of roughly $200 million. The acquisition brings Faeth’s lead drug PIKTOR — an oral combination that inhibits PI3K-alpha and dual mTORC1/2 — into Sensei’s pipeline. The funds are intended to advance PIKTOR through key clinical milestones (topline phase 2 data in advanced endometrial cancer and start of a phase 1b in HR+/HER2- breast cancer by the end of 2026), support development of Solnerstotug, and cover general corporate purposes. » Plus sur de.investing.com

Sensei Biotherapeutics announces it is halting development of the cancer drug Solnerstotug and has launched a strategic review to maximize shareholder value. Options include asset sales, licensing, partnerships, mergers, a sale of the company or an orderly wind‑down. The company plans job cuts, will retain a small team to meet regulatory obligations and to run the review process; there is no timeline or guarantee that a transaction will occur. Sensei says it has more cash than debt but continues to burn capital and will report quarterly results on November 7. » Plus sur de.investing.com